Ginkgo Bioworks Files SC 13D/A Amendment

TL;DR

Ginkgo Bioworks updated their stake in Bolt Projects Holdings on 8/30/24. Watch this space.

AI Summary

Ginkgo Bioworks, Inc. filed an amendment (SC 13D/A) on August 30, 2024, regarding their holdings in Bolt Projects Holdings, Inc. This filing indicates a change in beneficial ownership, though specific dollar amounts or percentage changes are not detailed in this excerpt. The filing is an update to a previous submission concerning their stake in Bolt Projects Holdings.

Why It Matters

This filing signals a potential shift in control or significant influence over Bolt Projects Holdings by Ginkgo Bioworks, which could impact the strategic direction and future operations of Bolt Projects Holdings.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate shifts in corporate control or strategy, which may affect the company's stock price and future performance.

Key Numbers

• 20240830 — Filing Date (Date of the SC 13D/A amendment filing)
• 20210119 — Name Change Date (Date Bolt Projects Holdings, Inc. changed its name from Golden Arrow Merger Corp.)

Key Players & Entities

• Ginkgo Bioworks, Inc. (company) — Filing entity and subject company
• Bolt Projects Holdings, Inc. (company) — Subject company of the filing
• Mark Dmytruk (person) — Chief Financial Officer of Ginkgo Bioworks, Inc., authorized to receive notices
• Golden Arrow Merger Corp. (company) — Former name of Bolt Projects Holdings, Inc.

FAQ

Key Financial Figures

• $0.0001 — relating to the common stock, par value $0.0001 per share (the Common Stock ) of Bolt P
• $4.8595 — inkgo Bioworks, Inc. 8/21/2024 206 $4.8595 (1) Sell Nasdaq Ginkgo Bioworks,
• $4.6846 — kgo Bioworks, Inc. 8/22/2024 1,004 $4.6846 (2) Sell Nasdaq Ginkgo Bioworks,
• $4.0809 — kgo Bioworks, Inc. 8/23/2024 6,800 $4.0809 (3) Sell Nasdaq Ginkgo Bioworks,
• $2.2407 — go Bioworks, Inc. 8/27/2024 16,461 $2.2407 (4) Sell Nasdaq Ginkgo Bioworks,
• $2.5144 — o Bioworks, Inc. 8/28/2024 653,475 $2.5144 (5) Sell Nasdaq Ginkgo Bioworks,
• $3.4581 — o Bioworks, Inc. 8/28/2024 135,101 $3.4581 (6) Sell Nasdaq Ginkgo Bioworks,
• $4.2560 — o Bioworks, Inc. 8/28/2024 371,826 $4.2560 (7) Sell Nasdaq Ginkgo Bioworks,
• $5.0679 — go Bioworks, Inc. 8/28/2024 41,711 $5.0679 (8) Sell Nasdaq (1) The price re
• $4.85 — ple transactions at prices ranging from $4.85 to $4.90. The Reporting Person undertak
• $4.90 — actions at prices ranging from $4.85 to $4.90. The Reporting Person undertakes to pro
• $4.50 — ple transactions at prices ranging from $4.50 to $4.9950. The Reporting Person undert
• $4.9950 — actions at prices ranging from $4.50 to $4.9950. The Reporting Person undertakes to pro
• $3.75 — ple transactions at prices ranging from $3.75 to $4.57. The Reporting Person undertak
• $4.57 — actions at prices ranging from $3.75 to $4.57. The Reporting Person undertakes to pro

Filing Documents

• d884114dsc13da.htm (SC 13D/A) — 76KB
• 0001193125-24-211058.txt ( ) — 78KB

herein

Item 5 herein. 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (2) 14. TYPE OF REPORTING PERSON (see instructions) CO (1) Consists of 1,452,735 shares of Common Stock of the Issuer held by Ginkgo Bioworks, a wholly owned subsidiary of Ginkgo. Shares of Common Stock of the Issuer held by Ginkgo Bioworks may be deemed beneficially owned by Ginkgo, its sole parent. (2) Based on 31,660,231 shares of Common Stock of the Issuer outstanding as of August 13, 2024, as reported on the Issuers Form 8-K filed August 19, 2024. CUSIP No. 09769B107 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Ginkgo Bioworks Holdings, Inc. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) 3. SEC USE ONLY 4. SOURCE OF FUNDS (see instructions) OO 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. SOLE VOTING POWER 0 8. SHARED VOTING POWER 1,452,735 (1) 9. SOLE DISPOSITIVE POWER 0 10. SHARED DISPOSITIVE POWER 1,452,735 (1) 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,452,735 (1) 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) See

herein

Item 5 herein. 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.6% (2) 14. TYPE OF REPORTING PERSON (see instructions) CO (1) Consists of 1,452,735 shares of Common Stock of the Issuer held by Ginkgo Bioworks, a wholly owned subsidiary of Ginkgo. Shares of Common Stock of the Issuer held by Ginkgo Bioworks may be deemed beneficially owned by Ginkgo, its sole parent. (2) Based on 31,660,231 shares of Common Stock of the Issuer outstanding as of August 13, 2024, as reported on the Issuers Form 8-K filed August 19, 2024. Explanatory Note This Schedule 13D/A constitutes Amendment No. 1 (this Amendment ) to the Schedule 13D (the Original Schedule 13D ) filed with the Securities and Exchange Commission on August 20, 2024 by Ginkgo Bioworks, Inc. and Ginkgo Bioworks Holdings, Inc. (together, the Reporting Persons ), relating to the common stock, par value $0.0001 per share (the Common Stock ) of Bolt Projects Holdings, Inc., a Delaware corporation (the Issuer ). Except as set forth herein, the Original Schedule 13D is unmodified and remains in full force and effect as to the Reporting Persons. Capitalized terms used but not defined herein shall have the meaning set forth in the Original Schedule 13D. Item5. Interest in Securities of the Issuer. Subparagraphs (a), (b), (c) and (e) of Item 5 of the Original Schedule 13D are amended and restated in their entirety as follows: (a) (b) The responses of the Reporting Persons to Rows (7) through (11), and (13) of the cover page of this Schedule 13D are incorporated herein by reference. To the knowledge of the Reporting Persons, none of the persons listed on Schedule A have any beneficial ownership of the Common Stock. (c) Except as described in this Item 5(c), the Reporting Persons nor, to the best of the knowledge of the Reporting Person, any of the persons listed in Schedule A , have not effected any transactions in the Class A Common Stock during the past 60 days. Schedule B sets forth the

View Full Filing

View this SC 13D/A filing on SEC EDGAR